Share

    


In This Section

Renal Cell Carcinoma

ACCC is devoted to providing up-to-date resources and education to help improve patient care and survival rates for those diagnosed with renal cell carcinoma (also known as kidney cancer).

Renal cell carcinoma is among the ten most common cancers in both men and women. Of those diagnosed with the disease, 15 – 25 percent have metastatic renal cell carcinoma (mRCC), which means the cancer has spread to other parts of the body.

Typically, renal cell carcinoma is a disease that affects older individuals; the average age at diagnosis is 64. In 2022, it is estimated that the U.S. will see about 79,000 new cases of renal cell carcinoma (50,290 in men and 28,710 in women), and that nearly 13,920 individuals will die from this disease.

Source: American Cancer Society. Key Statistics about Kidney Cancer.

Management of Treatment-related Adverse Events in RCC

This project will develop and facilitate surveys for patients and providers with the overall goal of facilitating optimized treatment options and improved care for patients diagnosed with metastatic RCC.

Learn More
Improving Quality Care in Renal Cell Carcinoma

ACCC's Improving Quality Care in Renal Cell Carcinoma project seeks to improve the quality of care for renal cell carcinoma patients treated at community cancer programs.

Learn More
Evolving Immunotherapeutic Landscape in RCC

This program is designed to provide a multidisciplinary care team with knowledge and resources to successfully address the practical issues and barriers associated with the integration of immunotherapies into the treatment of renal cell carcinoma.

Learn More

From Oncology Issues

Screen Shot 2021-04-12 at 12.29.15 PMThe Evolving Immunotherapeutic Landscape in Renal Cell Carcinoma
Robert A. Figlin, MD, FACP; Jocelyn Mohs, PharmD, BCOP; and Laura S. Wood, RN, MSN, OCN

In 2019 the Association of Community Cancer Centers developed an education program to provide all members of the multidisciplinary care team knowledge and resources to help successfully integrate immunotherapies into the treatment of patients with RCC.